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Summary. In a double-blind, randomized, placebo-controlled 
trial, the possible anti ischemic effect of metoprolol during 
percutaneous transluminal  coronary angioplasty was tested. 
Electrocardiograms, hemodynamics, and metabolism were 
studied in 27 patients with a stenosis in the left anterior de- 
scending coronary artery. Measurements ook place before 
angioplasty, after each of four 1-minute occlusions and 15 
minutes after the last balloon deflation. Patients were ran- 
domly given placebo or metoprolol (15 mg as a bolus intrave- 
nously, followed by an infusion of 0.04 mg/kg/hr). At the end 
of the procedure, the rate-pressure product had decreased by 
15% (NS) and 23% (p = 0.001) in the placebo and metoprolol 
groups, respectively, mainly due to similar decreases in heart 
rate. Metoprolol tended to lower chest pain and reduce pre- 
cordial ST-segment elevation due to angioplasty, but the ef- 
fects were not statistically significant. Lactate, hypoxan- 
thine, and urate release immediately after deflation was 
similar in both groups. Metoprolol reduced arterial plasma 
hypoxanthine throughout the procedure by about 30% (p -< 
0.02 vs. placebo). Thus, intravenous infusion of metoprolol 
did not significantly attenuate chest pain and ST-segment 
elevation, and failed to decrease cardiac lactate and oxypur- 
ine release. It did, however, reduce arterial hypoxanthine 
concentrations during angioplasty, possibly indicating that 
the beta-blocker inhibits extracardiac ATP catabolism. 
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Beta-adrenergic blockers are commonly used to treat 
stable angina and hypertension [1-3]. They relieve 
the symptoms of unstable angina [4]. Frishman and 
Chang [5] suggested that beta-blockers educe coro- 
nary thrombosis, myocardial infarction, and sudden 
death by attenuating the fracture of vulnerable ath- 
erosclerotic plaques, in addition to proven effects on 
heart rate, blood pressure, myocardial contractility, 
and ventricular ectopy [6,7]. Moreover they diminish 
postinfarction mortality, as proven in secondary pre- 
ventative studies [2,8]. 
In isolated hearts the nonselective beta-blocker 
propranolol exerts an energy-sparing effect during 
ischemia [9,10] and has strong chain-breaking antioxi- 
dant properties [11]. Beta-blockers, administered in- 
travenously orintracoronarily, diminish ischemia dur- 
ing acute coronary occlusion in humans [12,13]. 
Bonnier et al. [14] showed that a calcium entry 
blocker, diltiazem, could reduce oxypurine production 
from high-energy phosphates, induced by percutane- 
ous transluminal coronary angioplasty (PCTA). 
Thereby the drug diminished flow through the xan- 
thine oxidoreductase pathway, which could generate 
free radicals. In the present study, published in ab- 
stract form [15], we hypothesized that the beta1- 
selective blocker metoprolol could further attenuate 
ischemic injury during PTCA, e.g., by diminishing 
ATP breakdown. 
Methods 
Study population 
The trial involved 27 patients with one-vessel coro- 
nary artery disease undergoing PTCA. All patients 
had an isolated proximal stenosis in the left anterior 
descending artery (narrowing >80%), without demon- 
strable collaterals. Beta-blocker t eatment was dis- 
continued ->1 week before the procedure; other car- 
dioactive drugs were withheld 48 hours before the 
study. With the exception of heparin, no drugs were 
given during the investigation before completion of 
data acquisition. The institutional committee on pa- 
tient research approved the project. All patients gave 
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informed consent before the study; they did not suffer 
protocol-related complications. 
Coronary angioplasty 
The procedure has been described in detail earlier 
[14]. Briefly, a diagnostic atheter was introduced in 
the great cardiac vein. A guiding catheter was intro- 
duced percutaneously and advanced to the aortic root. 
The left anterior descending artery was visualized 
with contrast medium after the first venous and arte- 
rial samples were taken. Then PTCA was performed 
using a standard balloon catheter, with maximal in- 
flation pressures ranging from 6 to 12 atm. For each 
patient, the dilatations were sustained for 60 seconds, 
regardless of chest pain; four consecutive dilatations 
were done, with ->5 minutes between each inflation, 
and followed by control coronary angiography. Steno- 
sis diameter was determined independently b  three 
experienced cardiologists, using the digital calliper 
method. They measured the stenotic segment and 
compared it with the mean of adjacent normal seg- 
ments on an end-diastolic frame in at least two differ- 
ent angiographic projections. 
Experimental regimen 
The patients were andomly treated with placebo or 
beta-blocker (double blind). After baseline arterial 
and venous samples had been taken, three loading 
doses of 5 mg (5 ml) of a racemic mixture of S- and 
R-metoprolol tartrate (Seloken ®, Astra) or placebo (5 
ml saline) were rapidly injected intravenously at 2- 
minute intervals. Then the first dilatation took place. 
The bolus injections were followed by a continuous 
infusion of metoprolol 0.04 mg/kg/hr (or placebo) after 
the second balloon deflation. (For continuous use the 
drug was diluted with saline to 0.1 mg/ml.) Plasma 
metoprolol was determined gas chromatographically 
with electron capture detection [16]. 
Sampling 
Great cardiac venous and femoral arterial blood sam- 
ples, taken before, immediately after each deflation, 
and 15 minutes after the procedure, were processed 
as previously described [14]. 
Lactate and purine analysis 
In the deproteinized samples, lactate was determined 
enzymatically [17]. In addition, the ATP-catabolites 
hypoxanthine and urate were assayed by high- 
performance liquid chromatography [18], as modified 
by Huizer et al. [19]. Hypoxanthine and urate were 
detected at 254 and 290 nm, respectively. 
Electrocardiograms 
These were monitored from the precordial leads V2, 
V4, and V6, and the intracoronary lead, and analyzed 
as described before [14]. 
Pain 
At the end of each inflation, patient's chest discomfort 
was scored with Borg's new pain scale [20]. 
Statistical analysis 
The statistical package for social science (SPSS-X) 
was used for data analysis. Adequacy of metoprolol 
dosing was evaluated by comparing the post-PTCA 
heart-rate and double-product values with baseline 
data (Students' t-test). ECG variables and arteriove- 
nous differences were expressed as changes from 
baseline before being subject tomultivariate analysis. 
Analysis of variance with repeated measurements was 
used, with treatment and time as variables. Student's 
t-test was used for the between-group analysis, ex- 
cept for the comparison of the chest-discomfort rating 
scale (Mann-Whitney two-sample test). Unless other- 
wise stated, results are given as mean + standard 
error, p < 0.05 was considered significant. 
Results 
Clinical characteristics 
The study population was relatively homogeneous; for 
example, age and severity of the stenosis in the left 
anterior descending artery (Table 1), and ejection 
fraction of the left ventricle (not shown), in the two 
groups were similar. The disease of all patients was 
classified as Grade III of the Canadian Cardiovascular 
Society. They experienced angina pectoris only during 
exercise and received antianginal therapy. 
Inflation time, inflation pressure, and pain symp- 
toms during the four consecutive inflations were simi- 
lar in the metoprolol group (average 59.8 seconds, 11 
out of 12 patients with pain) and the placebo group 
(average 60.2 seconds, all 15 patients with pain). Due 
to coronary angioplasty, the cross-sectional rea of 
the stenosis decreased by about 85% in both groups 
(Table 1). No changes in nonstenotic coronary artery 
lumen diameter were observed. The baseline values 
of plasma lactate, hypoxanthine, and urate were simi- 
lar for both groups. 
Hemodynamics 
Systolic and diastolic blood pressure did not change 
significantly throughout the procedure (Figure 1). In 
the placebo group, heart rate decreased 15% 15 min- 
utes after the last deflation (p = 0.007 vs. baseline); 
in the metoprolol group, heart rate dropped by 23% 
(p < 0.001 vs. baseline, p = 0.03 vs. placebo). The 
rate-pressure product fell significantly only in the lat- 
ter (by 23%, p = 0.001). Metoprolol did not influence 
this variable significantly in comparison with placebo 
(Figure 1). 
Electrocardiographic measurements 
Precordial ST-segment changes (as the mean of the 
anterior wall leads Ve, V4, and V 6) tended to be 
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Table 1. Clinical characteristics of the study groups 
Variable 
Placebo Metoprolol 
group group 
(n = 15) (n = 12) 
Age (yrs) 
Average +_ SE 59 +- 2 57 -+ 2 
Range 46-75 42-72 
Sex: M/F 12/3 10/2 
Essential hypertension 1 1 
Hyperlipidemia 0 1 
Smokers (presently) 6 8 
Irregular heart rhythm 0 2 
Diabetes mellitus 1 0 
Diameter of stenosis (%) 
Before angioplasty 93.0 +_ 0.8 92.5 -+ 1.3 
After angioplasty 15.6 +_ 0.7 15.3 -+ 1.3 
None of the differences reached significance at p < 0.05. 
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Fig. 1. Hemodynamics before medication, after the bolus 
injections, and 15 minutes after the last deflation. Meto- 
prolol treatment (n = 12) induced a larger decrease in 
heart rate than placebo treatment (n = 15); however, the 
drop in rate-pressure product (RPP) did not differ signifi- 
cantly between the groups. 
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Fig. 2. Effect of metoprolol on precordiaI ST-segment 
changes, recovery of ST elevation, and chest pain during 
angioplasty. The pain scale is in arbitrary units: 0 = no 
pain; 10 = extremely strong pain. n = 9-15. 
smaller in the metoprolol group, but no statistically 
significant differences were found between the treat- 
ments (Figure 2). The absolute intracoronary and 
peak ST-segment changes, as well as the time to on- 
set of the ST changes, showed similar results. The 
time to recovery of ST-elevation--initially somewhat 
higher in the metoprolol group--a lso tended to de- 
crease under the influence of the drug, and to increase 
in the placebo group but the p value was 0.060 (NS, 
Figure 2). 
Chest pain 
The groups did not differ statistically with regard to 
pain experienced uring balloon inflation. However, 
the metoprolol group consistently scored less pain 
than the placebo group (Figure 2). 
Lactate metabolism 
The arterial lactate concentrations were lower in the 
metoprolol group than in the placebo group, but the 
drug did not significantly affect them (p = 0.059, Fig- 
ure 3). The same was true for the great cardiac venous 
lactate concentrations after angioplasty, which dou- 
bled in both groups. Also the arteriovenous difference 
in lactate was comparable between the groups. 
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Fig. 3. Effect of metoprolol on lactate metabolism of the 
heart. Drug treatment s arted after collection of baseline 
data. Immediately after angioplasty, lactate production 
was noted, as the great cardiac venous concentrations ex- 
ceeded the arterial ones. No significant effects of metc~pro- 
lol treatment were found, n = 12-15. 
Hypoxanthine metabolism 
The arterial and venous concentrations of hypoxan- 
thine are given in Figure 4. In both groups, the arte- 
rial concentrations fell after the first deflation and 
remained low. After each dilatation, the arterial hypo- 
xanthine concentrations in the metoprolol group were 
about 30% lower than in the placebo group (p -< 0.02). 
The great cardiac venous levels remained more or less 
constant during the study. The groups showed no sig- 
nificant differences in venous hypoxanthine concentra- 
tions or hypoxanthine production due to PTCA (Fig- 
ure 4). 
Urate release 
Metoprolol had no significant effect on the arterial and 
venous urate concentrations, nor on urate production 
by the heart. The initial arterial and venous values in 
the metoprolol group were 252 ± 20 ~LM and 250 - 
20 ~LM, respectively; in the placebo group, they were 
244 ± 9 ~LM and 243 ± 9 ~M, respectively. The con- 
centrations varied less than 10% throughout the pro- 
cedure (data not shown). Thirty percent of the hearts 
produced minor amounts of urate before PTCA, in 
contrast o the majority of hearts (usually 70%) after 
each deflation. 
Metoprolo l  levels 
The plasma concentrations of metoprolol, measured 5 
minutes after the last deflation, varied relatively little 
(164 ± 18 riM). 
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Fig. 4. Effect of metoprolol on arterial and great cardiac 
venous hypoxanthine concentrations. Treatment with 
beta-blocker lowered the arterial concentration during the 
procedure significantly. However, cardiac hypoxanthine 
production due to angioplasty was not significantly influ- 
enced, n = 12-15. 
Discussion 
Metoprolo l  ef fects  
We were unable to confirm our hypothesis that meto- 
prolol could attenuate signs of ischemia during PTCA. 
Intravenous infusion of metoprolol tended to attenu- 
ate chest pain and ST-segment elevation, but failed to 
affect cardiac lactate and oxypurine release. It did, 
however, reduce significantly the arterial hypoxan- 
thine concentrations during angioplasty, possibly indi- 
cating that the beta-blocker inhibits extracardiac ATP 
catabolism. 
Metoprolo l  dosing 
The plasma levels measured at the end of the proce- 
dure were within the therapeutic range for metoprolol 
[21]. We observed the expected rop in heart rate and 
double product (Figure 1), indicating that the drug 
partially suppressed the beta-adrenergic system of 
the patients. The Lime effects found with some vari- 
ables, e.g., recovery from ST-segment elevation, are 
perhaps due to metoprolol accumulation i cardiac tis- 
sue [22]. 
ECG changes and chest pain 
The leads used included those optimal for monitoring 
ischemia of the area perfused by the left anterior de- 
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scending coronary artery [23]. We did not detect a 
statistically significant effect of metoprolol treatment 
on ST-segment changes or chest pain during coronary 
angioplasty (Figure 2). However, the ST-segment 
changes and chest pain tended to be smaller in the 
metoprolol group. Labovitz et al. [24] recently ob- 
served some decrease of duration and extent of maxi- 
real ST-segment elevation during angioplasty by ul- 
trashort-lasting beta-adrenergic blockade. Metoprolol 
administration is highly effective in reducing ambula- 
tory ischemia, as evidenced by ST depression during 
daily life [25]. 
Lactate production 
Metoprolol was without effect on cardiac lactate me- 
tabolism (Figure 3). The drug tended to reduce the 
arterial lactate levels, which is in line with the findings 
in healthy subjects [26] and with the reduction of arte- 
rial hypoxanthine (vide infra). The decrease in arterial 
lactate is possibly due to impaired translocation of lac- 
tate from the sites of production [27]. 
Oxgpurine metabol ism 
After ischemia, the human heart releases hypoxan- 
thine due to ATP catabolism [14,18,28-30]. In con- 
trast to earlier work [14,30], coronary occlusion did 
not influence venous hypoxanthine. Still the arteriove- 
nous difference became negative, because the arterial 
levels fell. The difference from earlier studies i the 
somewhat shorter balloon inflation time, which could 
explain the discrepancy. 
Metoprolol reduced the arterial hypoxanthine con- 
centrations during the procedure (Figure 4). This 
could indicate that the drug attenuates extracardiac 
ATP breakdown. In fact, there is some in vitro evi- 
dence that beta-blockade depresses ATPase activity 
[31]. The clinical significance of the reduction in arte- 
rial hypoxanthine remains to be elucidated. It  would 
be of interest o know whether metoprolol also modu- 
lates the concentration of the hypoxanthine precursor 
adenosine, a regulator of many physiological pro- 
cesses. 
The appearance of urate indicates that human heart 
contains ome xanthine oxidoreductase activity [29]. 
On the other hand, perfusion of explanted human 
hearts with hypoxanthine gives rise to negligible 
urate production [32]. We still have to learn whether 
human heart contains the desulpho form of xanthine 
oxidase, which generates free radicals but not urate 
[33]. 
Conc lus ions  
Intravenous infusion of metoprolol did not signifi- 
cantly attenuate PCTA-induced signs of ischemia. 
Therefore this form of therapy should not be consid- 
ered appropriate for all patients undergoing PTCA. 
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